Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02900651
Title Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | CAN

Facility Status City State Zip Country Details
UCSF . San Francisco California 94115 United States Details
UCLA Santa Monica Hematology Oncology Santa Monica California 90404 United States Details
Uni Of TX MD Anderson Cancer Cntr Dept of Onc Houston Texas 77030 United States Details
Novartis Investigative Site Toronto Ontario M5G 2M9 Canada Details
Novartis Investigative Site Chengdu Sichuan 610041 China Details
Novartis Investigative Site Shanghai 200032 China Details
Novartis Investigative Site Villejuif 94800 France Details
Novartis Investigative Site Freiburg 79106 Germany Details
Novartis Investigative Site Koeln 50937 Germany Details
Novartis Investigative Site Hong Kong Hong Kong Details
Novartis Investigative Site Milano MI 20133 Italy Details
Novartis Investigative Site Rozzano MI 20089 Italy Details
Novartis Investigative Site Fukuoka-city Fukuoka 811-1395 Japan Details
Novartis Investigative Site Sunto Gun Shizuoka 411 8777 Japan Details
Novartis Investigative Site Singapore 168583 Singapore Details
Novartis Investigative Site Madrid 28041 Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field